5:31 PM
 | 
Oct 08, 2013
 |  BC Extra  |  Company News

FDA accepts Keryx's Zerenex NDA

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) said FDA accepted for review an NDA for Zerenex ferric citrate to treat hyperphosphatemia in chronic kidney disease...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >